The Oncosearch | Oncotarget

CAR-T therapy: Trailblazing CAR(ing) in cancer treatment Editorial Perspective

Uzma Saqib, Monika Pandey, Krishnan Hajela

Published Mar 20, 2026 · Vol. 17, No. 1 · pp. 54-56

Keywords: CAR-T therapy, cancer, therapeutic approaches

Correction: Tissue biodistribution and tumor targeting of near-infrared labelled anti-CD38 antibody-drug conjugate in preclinical multiple myeloma Correction

Nicholas Cho, Sooah Ko, Monica Shokeen

Published Apr 11, 2025 · Vol. 16, No. 1 · pp. 273-274

NSD2-epigenomic reprogramming and maintenance of plasma cell phenotype in t(4;14) myeloma Research Paper

Andrea Gunnell, Scott T. Kimber, Richard Houlston, Martin Kaiser

Published Mar 16, 2025 · Vol. 16, No. 1 · pp. 220-229

Keywords: myeloma, NSD2, t(4;14), CD38, plasma cell

GZ17-6.02 interacts with proteasome inhibitors to kill multiple myeloma cells Research Paper

Laurence Booth, Jane L. Roberts, Cameron West, Paul Dent

Published Jan 29, 2024 · Vol. 15, No. 1 · pp. 159-174

Keywords: autophagy, ER stress, GZ17-6.02, bortezomib, proteasome inhibitor

Bone marrow adipocytes provide early sign for progression from MGUS to multiple myeloma Research Perspective

Bilal M. El-Masri, Benedeta Leka, Fatima Mustapha, Michael Tveden Gundesen, Maja Hinge, Thomas Lund, Thomas L. Andersen, Marta Diaz-delCastillo, Abbas Jafari

Published Jan 2, 2024 · Vol. 15, No. 1 · pp. 20-26

Keywords: multiple myeloma, MGUS, bone marrow adipocyte

Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma Research Perspective

Ashley Del Dosso, Elizabeth Tadevosyan, James R. Berenson

Published Dec 23, 2023 · Vol. 15, No. 1 · pp. 65-75

Keywords: multiple myeloma, ruxolitinib, JAK/STAT, cytokine, clinical trial

Plasma levels of BCMA-positive extracellular vesicles correlate to response and side effects in myeloma patients treated with belantamab-mafodotin Research Paper

Carsten Springer, Jürgen Krauter, Arne Trummer

Published Nov 23, 2023 · Vol. 14, No. 1 · pp. 949-956

Keywords: myeloma, b cell maturation antigen, extracellular vesicles, belantamab-mafodotin, eryptosis

Correction: HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide Correction

Alessandro Canella, Hector Cordero Nieves, Douglas W. Sborov, Luciano Cascione, Hanna S. Radomska, Emily Smith, Andrew Stiff, Jessica Consiglio, Enrico Caserta, Lara Rizzotto, Nicola Zanesi, Volinia Stefano, Balveen Kaur, Xiaokui Mo, John C. Byrd, Yvonne A. Efebera, Craig C. Hofmeister, Flavia Pichiorri

Published Sep 23, 2023 · Vol. 14, No. 1 · pp. 837-838

LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair Research Paper

Jianli Zhou, Drew Sturtevant, Cassie Love, Aditya Kulkarni, Neha Biyani, Umesh Kathad, Elizabeth Thacker, Sandeep Dave, Kishor Bhatia

Published Jun 5, 2023 · Vol. 14, No. 1 · pp. 597-611

Keywords: non-Hodgkin's lymphoma, DNA damage, homologous recombination repair, transcription-coupled nucleotide excision repair, ATM

The hope for targeting fatty acid binding proteins in multiple myeloma Editorial

Heather Fairfield, Michaela R. Reagan

Published May 12, 2023 · Vol. 14, No. 1 · pp. 612-613

Keywords: multiple myeloma, FABPs, fatty acid binding proteins, immunoncology, pre-clinical discovery

Systemic AL amyloidosis: current approach and future direction Review

Maroun Bou Zerdan, Lewis Nasr, Farhan Khalid, Sabine Allam, Youssef Bouferraa, Saba Batool, Muhammad Tayyeb, Shubham Adroja, Mahinbanu Mammadii, Faiz Anwer, Shahzad Raza, Chakra P. Chaulagain

Published Apr 19, 2023 · Vol. 14, No. 1 · pp. 384-394

Keywords: amyloidosis, management

Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659) Research Paper

Leo I. Gordon, Reem Karmali, Jason B. Kaplan, Rakesh Popat, Howard A. Burris III, Silvia Ferrari, Sumit Madan, Manish R. Patel, Giuseppe Gritti, Dima El-Sharkawi, F. Ian Chau, John Radford, Jaime Pérez de Oteyza, Pier Luigi Zinzani, Swaminathan P. Iyer, William Townsend, Harry Miao, Igor Proscurshim, Shining Wang, Shilpi Katyayan, Ying Yuan, Jiaxi Zhu, Kate Stumpo, Yaping Shou, Cecilia Carpio, Francesc Bosch

Published Jan 20, 2023 · Vol. 14, No. 1 · pp. 57-70

Keywords: Non-Hodgkin’s lymphoma, DLBCL, relapsed/refractory, SYK inhibitor, TAK-659

To be or not to be: the role of CD56 in multiple myeloma Editorial

Francesca Cottini, Don Benson

Published Jan 18, 2023 · Vol. 14, No. 1 · pp. 47-49

Keywords: myeloma, targeted therapies, CD56, signaling

Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001 Research Paper

Xiaofan Li, Cristina Abrahams, Abigail Yu, Millicent Embry, Robert Henningsen, Venita DeAlmeida, Shannon Matheny, Toni Kline, Alice Yam, Ryan Stafford, Trevor Hallam, Mark Lupher, Arturo Molina

Published Dec 27, 2022 · Vol. 14, No. 1 · pp. 1-13

Keywords: CD74, antibody-drug conjugate, non-Hodgkin lymphoma, xenograft models, STRO-001

The serine protease matriptase inhibits migration and proliferation in multiple myeloma cells Research Paper

Ida Steiro, Esten N. Vandsemb, Samah Elsaadi, Kristine Misund, Anne-Marit Sponaas, Magne Børset, Pegah Abdollahi, Tobias S. Slørdahl

Published Oct 15, 2022 · Vol. 13, No. 1 · pp. 1175-1186

Keywords: matriptase, multiple myeloma, tumor suppressor, migration, Src

Correction: Adipocytes secreted leptin is a pro-tumor factor for survival of multiple myeloma under chemotherapy Correction

Wen Yu, De-Dong Cao, Qiu-bai Li, Hui-ling Mei, Yu Hu, Tao Guo

Published May 11, 2022 · Vol. 14, No. 1 · pp. 821-823

Transplantation of autologous bone marrow pre-loaded ex vivo with oncolytic myxoma virus is efficacious against drug-resistant Vk*MYC mouse myeloma Research Paper

Nancy Y. Villa, Masmudur M. Rahman, Joseph Mamola, Meaghen E. Sharik, Ana Lemos de Matos, Jacquelyn Kilbourne, Kenneth Lowe, Juliane Daggett-Vondras, Julia D'Isabella, Elizabeth Goras, Marta Chesi, P. Leif Bergsagel, Grant McFadden

Published Feb 21, 2022 · Vol. 13, No. 1 · pp. 490-504

Keywords: myxoma virus, multiple myeloma, combination therapy, autologous transplantation, oncolytic virus

Correction: Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma Correction

De-Xiu Bu, Reshma Singh, Eugene E. Choi, Marco Ruella, Selene Nunez-Cruz, Keith G. Mansfield, Paul Bennett, Nathanial Barton, Qilong Wu, Jiquan Zhang, Yongqiang Wang, Lai Wei, Shawn Cogan, Tucker Ezell, Shree Joshi, Kellie J. Latimer, Brian Granda, William R. Tschantz, Regina M. Young, Heather A. Huet, Celeste J. Richardson, Michael C. Milone

Published Nov 2, 2021

Tissue biodistribution and tumor targeting of near-infrared labelled anti-CD38 antibody-drug conjugate in preclinical multiple myeloma Research Paper

Nicholas Cho, Sooah Ko, Monica Shokeen

Published Sep 7, 2021 · Vol. 12, No. 20 · pp. 2039-2050

Keywords: near-infrared (NIR) fluorescence, multiple myeloma (MM), cluster of differentiation 38 (CD38), antibody-drug conjugate (ADC), small animal optical imaging

TAK1-inhibitors are cytotoxic for multiple myeloma cells alone and in combination with melphalan Research Paper

Erling Håland, Ingrid Nyhus Moen, Elias Veidal, Hanne Hella, Kristine Misund, Tobias S. Slørdahl, Kristian K. Starheim

Published Sep 4, 2021 · Vol. 12, No. 21 · pp. 2158-2168

Keywords: multiple myeloma, TAK1, apoptosis, NF-κB, cancer treatment

Publication Alerts

European Cancer and Oncology Congress

Post-Publication Promotion

Search Oncotarget

CAR-T therapy: Trailblazing CAR(ing) in cancer treatment Editorial Perspective

Correction: Tissue biodistribution and tumor targeting of near-infrared labelled anti-CD38 antibody-drug conjugate in preclinical multiple myeloma Correction

NSD2-epigenomic reprogramming and maintenance of plasma cell phenotype in t(4;14) myeloma Research Paper

GZ17-6.02 interacts with proteasome inhibitors to kill multiple myeloma cells Research Paper

Bone marrow adipocytes provide early sign for progression from MGUS to multiple myeloma Research Perspective

Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma Research Perspective

Plasma levels of BCMA-positive extracellular vesicles correlate to response and side effects in myeloma patients treated with belantamab-mafodotin Research Paper

Correction: HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide Correction

LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair Research Paper

The hope for targeting fatty acid binding proteins in multiple myeloma Editorial

Systemic AL amyloidosis: current approach and future direction Review

Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659) Research Paper

To be or not to be: the role of CD56 in multiple myeloma Editorial

Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001 Research Paper

The serine protease matriptase inhibits migration and proliferation in multiple myeloma cells Research Paper

Correction: Adipocytes secreted leptin is a pro-tumor factor for survival of multiple myeloma under chemotherapy Correction

Transplantation of autologous bone marrow pre-loaded ex vivo with oncolytic myxoma virus is efficacious against drug-resistant Vk*MYC mouse myeloma Research Paper

Correction: Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma Correction

Tissue biodistribution and tumor targeting of near-infrared labelled anti-CD38 antibody-drug conjugate in preclinical multiple myeloma Research Paper

TAK1-inhibitors are cytotoxic for multiple myeloma cells alone and in combination with melphalan Research Paper

Publication Alerts

European Cancer and Oncology Congress

Oncoscience

Post-Publication Promotion

Search Oncotarget

CAR-T therapy: Trailblazing CAR(ing) in cancer treatment Editorial Perspective

Correction: Tissue biodistribution and tumor targeting of near-infrared labelled anti-CD38 antibody-drug conjugate in preclinical multiple myeloma Correction

NSD2-epigenomic reprogramming and maintenance of plasma cell phenotype in t(4;14) myeloma Research Paper

GZ17-6.02 interacts with proteasome inhibitors to kill multiple myeloma cells Research Paper

Bone marrow adipocytes provide early sign for progression from MGUS to multiple myeloma Research Perspective

Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma Research Perspective

Plasma levels of BCMA-positive extracellular vesicles correlate to response and side effects in myeloma patients treated with belantamab-mafodotin Research Paper

Correction: HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide Correction

LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair Research Paper

The hope for targeting fatty acid binding proteins in multiple myeloma Editorial

Systemic AL amyloidosis: current approach and future direction Review

Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659) Research Paper

To be or not to be: the role of CD56 in multiple myeloma Editorial

Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001 Research Paper

The serine protease matriptase inhibits migration and proliferation in multiple myeloma cells Research Paper

Correction: Adipocytes secreted leptin is a pro-tumor factor for survival of multiple myeloma under chemotherapy Correction

Transplantation of autologous bone marrow pre-loaded ex vivo with oncolytic myxoma virus is efficacious against drug-resistant Vk*MYC mouse myeloma Research Paper

Correction: Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma Correction

Tissue biodistribution and tumor targeting of near-infrared labelled anti-CD38 antibody-drug conjugate in preclinical multiple myeloma Research Paper

TAK1-inhibitors are cytotoxic for multiple myeloma cells alone and in combination with melphalan Research Paper